Medtronic Hires Dr James Porter, One of the Nation’s Top Surgeons as CMO

Dr. James Porter will represent the company this week — including from the Hugo™ console to perform a live partial nephrectomy — at Europe’s biggest urology conference

Medtronic, a global leader in healthcare technology, today announced that Dr James Porter has joined the company as chief medical officer (CMO) of Robotic Surgical Technologies and Digital Technologies within the Surgical business, which is part of the Medical Surgical Portfolio.

A practicing urologic surgeon who has performed more than 5,000 robotic-assisted procedures, Dr James Porter is a recognized leader among the global surgical community and one of the top five robotic surgery practitioners in the U.S.

He specializes in prostate, kidney cancer, and urinary constructive procedures and his contributions to the field of urologic surgery include the advancement of several groundbreaking surgical techniques employed to treat kidney tumors and testicular cancer in young men.

“I went into medicine because I want to help people and I am absolutely thrilled to now expand the impact on patients to a global scale with Medtronic, a company that I have always admired,” Dr. Porter said. “Tens of millions of patients around the world still lack access to minimally invasive surgical care and I’m excited about our opportunity at Medtronic to make a big impact for humanity. Surgery is fast evolving, due in large part to robotic and digital technologies, and HugoTM and Touch SurgeryTM are leading the way.”

As medical director of robotic surgery with Providence Swedish in Seattle, Wash., part of the larger Providence healthcare system, Dr. Porter helped build one of the highest volume, multispecialty robotic surgery programs in the U.S. He will continue to practice surgery, on a part-time basis, at Providence Swedish.

“Medtronic is privileged to welcome such a renowned physician to our business, and we look forward to Dr. Porter’s contributions as CMO of our robotic and digital divisions as we execute our strategy to scale and continually advance our capabilities to meet customer needs and positively impact patients around the world,” said Rajit Kamal, general manager and vice president of Robotic Surgical Technologies within the Surgical business, which is part of the Medical Surgical Portfolio at Medtronic.

As CMO of robotic and digital technologies within Medtronic’s Surgical business, Dr. Porter will play a key role in driving focus on patients, robotic and digital innovation, the strategic direction of clinical evidence plans, and physician and society engagements.

This week, Dr. Porter will join urologic surgeons from around the world at the European Robotic Urology Society (ERUS) conference, which takes place in Bordeaux, France, from Sept. 11-13.

The conference’s live surgery section will include 12 HugoTM cases, including a partial nephrectomy performed by Dr. Porter. A platinum sponsor of ERUS, Medtronic will also conduct in-booth demos of HugoTM and Touch SurgeryTM Ecosystem, including the recently added Live Stream technology, which securely welcomes remote participants into the live surgery.

SourceMedtronic

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version